Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI Tumor
Status:
Unknown status
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Malnutrition is frequently seen in patients on chemotherapy suffering from gastric/colorectal
cancer and may worsen the outcome. EPA, a sort of ω-3 PUFA, can modulate immune system. EPA
also antagonizes metabolic and inflammatory changes induced by the tumor. This study is to
test whether EPA, in combination with enteral nutrition, can improve nutritional/immunologic
status, quality of life, and reduce chemotherapy related side effects of these patients.